Blood and marrow transplant clinical trials network state of the Science Symposium 2014

Frederick R Appelbaum, Claudio Anasetti, Joseph H Antin, Harold Atkins, Stella Davies, Steven Devine, Sergio Giralt, Helen Heslop, Ginna Laport, Stephanie J Lee, Brent Logan, Marcelo Pasquini, Michael Pulsipher, Edward Stadtmauer, John R Wingard, Mary M Horowitz, Frederick R Appelbaum, Claudio Anasetti, Joseph H Antin, Harold Atkins, Stella Davies, Steven Devine, Sergio Giralt, Helen Heslop, Ginna Laport, Stephanie J Lee, Brent Logan, Marcelo Pasquini, Michael Pulsipher, Edward Stadtmauer, John R Wingard, Mary M Horowitz

No abstract available

Keywords: Hematopoietic cell transplantation; Leukemia; Lymphoma; Myeloma.

Conflict of interest statement

Conflict of interest statement: There are no conflicts of interest to report.

Figures

Figure 1

The overall trial design depends on assignment to a high- or low-risk group based on GVHD grade and biomarkers. High-risk patients will be treated with prednisone, and new agents will be serially studied by addition to standard prednisone therapy. Low-risk patients will be randomized between a prednisone monotherapy or 1 of several single-agent nonsteroid alternatives.